BACKGROUND AND OBJECTIVES: It is unclear how to optimally care for chronic kidney disease (CKD). This study compares a new coordinated model to usual care for CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A randomized trial in nephrology clinics and the community included 474 patients with median estimated GFR (eGFR) 42 ml/min per 1.73 m(2) identified by laboratory-based case finding compared care coordinated by a general practitioner (controls) with care by a nurse-coordinated team including a nephrologist (intervention) for a median (interquartile range [IQR]) of 742 days. 32% were diabetic, 60% had cardiovascular disease, and proteinuria was minimal. Guided by protocols, the intervention team targeted risk factors for adverse kidney and cardiovascular outcomes. Serial eGFR and clinical events were tracked. RESULTS: The average decline in eGFR over 20 months was -1.9 ml/min per 1.73 m(2). eGFR declined by ≥4 ml/min per 1.73 m(2) within 20 months in 28 (17%) intervention patients versus 23 (13.9%) control patients. Control of BP, LDL, and diabetes were comparable across groups. In the intervention group there was a trend to greater use of renin-angiotensin blockers and more use of statins in those with initial LDL >2.5 mmol/L. Treatment was rarely required for anemia, acidosis, or disordered mineral metabolism. Clinical events occurred in 5.2% per year. CONCLUSIONS:Patients with stage 3/4 CKD identified through community laboratories largely had nonprogressive kidney disease but had cardiovascular risk. Over a median of 24 months, the nurse-coordinated team did not affect rate of GFR decline or control of most risk factors compared with usual care.
RCT Entities:
BACKGROUND AND OBJECTIVES: It is unclear how to optimally care for chronic kidney disease (CKD). This study compares a new coordinated model to usual care for CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A randomized trial in nephrology clinics and the community included 474 patients with median estimated GFR (eGFR) 42 ml/min per 1.73 m(2) identified by laboratory-based case finding compared care coordinated by a general practitioner (controls) with care by a nurse-coordinated team including a nephrologist (intervention) for a median (interquartile range [IQR]) of 742 days. 32% were diabetic, 60% had cardiovascular disease, and proteinuria was minimal. Guided by protocols, the intervention team targeted risk factors for adverse kidney and cardiovascular outcomes. Serial eGFR and clinical events were tracked. RESULTS: The average decline in eGFR over 20 months was -1.9 ml/min per 1.73 m(2). eGFR declined by ≥4 ml/min per 1.73 m(2) within 20 months in 28 (17%) intervention patients versus 23 (13.9%) control patients. Control of BP, LDL, and diabetes were comparable across groups. In the intervention group there was a trend to greater use of renin-angiotensin blockers and more use of statins in those with initial LDL >2.5 mmol/L. Treatment was rarely required for anemia, acidosis, or disordered mineral metabolism. Clinical events occurred in 5.2% per year. CONCLUSIONS:Patients with stage 3/4 CKD identified through community laboratories largely had nonprogressive kidney disease but had cardiovascular risk. Over a median of 24 months, the nurse-coordinated team did not affect rate of GFR decline or control of most risk factors compared with usual care.
Authors: E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz Journal: N Engl J Med Date: 2001-09-20 Impact factor: 91.245
Authors: Allen R Nissenson; Allan J Collins; Judith Hurley; Hans Petersen; Brian J G Pereira; Earl P Steinberg Journal: J Am Soc Nephrol Date: 2001-08 Impact factor: 10.121
Authors: Robert B Hopkins; Amit X Garg; Adeera Levin; Anita Molzahn; Claudio Rigatto; Joel Singer; George Soltys; Steven Soroka; Patrick S Parfrey; Brendan J Barrett; Ron Goeree Journal: Clin J Am Soc Nephrol Date: 2011-05-26 Impact factor: 8.237
Authors: Nynke D Scherpbier-de Haan; Gerald M M Vervoort; Chris van Weel; Jozé C C Braspenning; Jan Mulder; Jack F M Wetzels; Wim J C de Grauw Journal: Br J Gen Pract Date: 2013-12 Impact factor: 5.386
Authors: Ping Liu; Robert R Quinn; Mohammad Ehsanul Karim; Aminu Bello; Helen Tam-Tham; Robert Weaver; Paul E Ronksley; Hude Quan; Giovanni F M Strippoli; Braden Manns; Brenda R Hemmelgarn; Marcello Tonelli; Pietro Ravani Journal: CMAJ Date: 2019-03-11 Impact factor: 8.262
Authors: Pim P Valentijn; Fernando Abdalla Pereira; Marinella Ruospo; Suetonia C Palmer; Jörgen Hegbrant; Christina W Sterner; Hubertus J M Vrijhoef; Dirk Ruwaard; Giovanni F M Strippoli Journal: Clin J Am Soc Nephrol Date: 2018-02-09 Impact factor: 8.237
Authors: Samuel A Silver; Chaim M Bell; Glenn M Chertow; Prakesh S Shah; Kaveh Shojania; Ron Wald; Ziv Harel Journal: Clin J Am Soc Nephrol Date: 2017-09-06 Impact factor: 8.237
Authors: Mieke J Peeters; Arjan D van Zuilen; Jan A J G van den Brand; Michiel L Bots; Marjolijn van Buren; Marc A G J Ten Dam; Karin A H Kaasjager; Gerry Ligtenberg; Yvo W J Sijpkens; Henk E Sluiter; Peter J G van de Ven; Gerald Vervoort; Louis-Jean Vleming; Peter J Blankestijn; Jack F M Wetzels Journal: J Am Soc Nephrol Date: 2013-10-24 Impact factor: 10.121
Authors: Brendon L Neuen; Hocine Tighiouart; Hiddo J L Heerspink; Edward F Vonesh; Juhi Chaudhari; Shiyuan Miao; Tak Mao Chan; Fernando C Fervenza; Jürgen Floege; Marian Goicoechea; William G Herrington; Enyu Imai; Tazeen H Jafar; Julia B Lewis; Philip Kam-Tao Li; Francesco Locatelli; Bart D Maes; Ronald D Perrone; Manuel Praga; Annalisa Perna; Francesco P Schena; Christoph Wanner; Jack F M Wetzels; Mark Woodward; Di Xie; Tom Greene; Lesley A Inker Journal: J Am Soc Nephrol Date: 2021-12-03 Impact factor: 10.121
Authors: Jia Liang Kwek; Konstadina Griva; Navreen Kaur; Kay Yuan Chong; Zi Yang Chua; Gim Hong Andy Sim; Li Choo Ng; Pay Wen Yong; Yu-Tzu Tung; Lydia Wei Wei Lim; Su Hooi Teo; Jason Chon Jun Choo; Marjorie Wai Yin Foo; Tazeen Hasan Jafar Journal: Int Urol Nephrol Date: 2021-07-22 Impact factor: 2.370
Authors: Celia C Kamath; Claudia C Dobler; Rozalina G McCoy; Michelle A Lampman; Atieh Pajouhi; Patricia J Erwin; John Matulis; Muhamad Elrashidi; Joseph Darcel; Mouaz Alsawas; Zhen Wang; Nilay D Shah; M Hassan Murad; Bjorg Thorsteinsdottir Journal: J Gen Intern Med Date: 2020-10-26 Impact factor: 5.128